期刊
JOURNAL OF CLINICAL INVESTIGATION
卷 119, 期 6, 页码 1524-1536出版社
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI37869
关键词
-
资金
- NIH [CA116548, CA81403, CA60104]
- Neil Bogart Memorial Fund
- T.J. Martell Foundation for Leukemia, Cancer, and AIDS Research
- NATIONAL CANCER INSTITUTE [U01CA060104, R01CA060104, P01CA081403, R01CA116548] Funding Source: NIH RePORTER
Tumor infiltration with V alpha 24-invariant NKT cells (NKTs) associates with favorable outcome in neuroblastoma and other cancers. Although NKTs can be directly cytotoxic against CD1d(+) cells, the majority of human tumors are CD1d(-). Therefore, the role of NKTs in cancer remains largely unknown. Here, we demonstrate that CD68(+) tumor-associated monocytes/macrophages (TAMs) represented the majority of CD1d-expressing cells in primary human neuroblastomas. TAMs stimulated neuroblastoma growth in human cell fines and their xenografts in NOD/SCID mice via IL-6 production. Indeed, TAMs produced IL-6 in primary tumors and in the BM of patients with metastatic neuroblastoma. Gene expression analysis using TaqMan low-density arrays of 129 primary human neuroblastomas without MYCN amplification revealed that high-level expression of TAM-specific genes (CD14, CD16, IL6, IL6R, and TGFB1) was associated with poor 5-year event-free survival. While NKTs were not cytotoxic against neuroblastoma. cells, they effectively killed monocytes pulsed with tumor cell lysate. The killing of monocytes was CD1d restricted because it was inhibited by a CD1d-specific mAb. Cotransfer of human monocytes and NKTs to tumor-bearing NOD/SCID mice decreased monocyte number at the tumor site and suppressed tumor growth compared with mice transferred with monocytes alone. Thus, killing of TAMs reveals what we believe to be a novel mechanism of NKT antitumor activity that relates to the disease outcome.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据